ceritinib
General
High Alert Medication: This medication bears a heightened risk of causing significant patient harm when it is used in error.
Genetic Implications:
Pronunciation:
se-ri-ti-nib

Trade Name(s)
- Zykadia
Ther. Class.
Pharm. Class.
kinase inhibitors
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., et al. "Ceritinib." Davis's Drug Guide, 19th ed., F.A. Davis Company, 2025. Nursing Central, nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/110150/0/ceritinib.
Vallerand AHA, Sanoski CAC, . Ceritinib. Davis's Drug Guide. F.A. Davis Company; 2025. https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/110150/0/ceritinib. Accessed February 23, 2025.
Vallerand, A. H., Sanoski, C. A., & , (2025). Ceritinib. In Davis's Drug Guide (19th ed.). F.A. Davis Company. https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/110150/0/ceritinib
Vallerand AHA, Sanoski CAC, . Ceritinib [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2025. [cited 2025 February 23]. Available from: https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/110150/0/ceritinib.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - ceritinib
ID - 110150
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
AU - ,,
BT - Davis's Drug Guide
UR - https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/110150/0/ceritinib
PB - F.A. Davis Company
ET - 19
DB - Nursing Central
DP - Unbound Medicine
ER -